Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tuparstobart in Uveal Melanoma: NCT03538028 Clinical Landscape Report 2026
16 October 2026
NCT03538028 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologous Dendritic Cell vaccine(Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori) in Mesothelioma, Malignant: NCT03546426 Clinical Landscape Report 2026
16 October 2026
NCT03546426 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fitusiran in Hemophilia B: NCT03549871 Clinical Landscape Report 2026
16 October 2026
NCT03549871 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Avicursen in Musculoskeletal Diseases: ACTRN12618000970246 Clinical Landscape Report 2026
16 October 2026
ACTRN12618000970246 clinical landscape for Musculoskeletal Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
VMD-928 in Advanced Head and Neck Carcinoma: NCT03556228 Clinical Landscape Report 2026
16 October 2026
NCT03556228 clinical landscape for Advanced Head and Neck Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Poloxamer 188(CytRx Corp.) in Muscular Dystrophy, Duchenne: NCT03558958 Clinical Landscape Report 2026
16 October 2026
NCT03558958 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Coagulation Factor IX (Recombinant) in Hemophilia B: NCT03565237 Clinical Landscape Report 2026
16 October 2026
NCT03565237 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Malignant Pleural Mesothelioma: NCT03560973 Clinical Landscape Report 2026
16 October 2026
NCT03560973 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Idebenone in Muscular Dystrophy, Duchenne: NCT03603288 Clinical Landscape Report 2026
16 October 2026
NCT03603288 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amifampridine phosphate in Myasthenia Gravis: NCT03579966 Clinical Landscape Report 2026
16 October 2026
NCT03579966 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MK-4830 in Pancreatic adenocarcinoma: NCT03564691 Clinical Landscape Report 2026
16 October 2026
NCT03564691 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DTX-201 in Hemophilia A: NCT03588299 Clinical Landscape Report 2026
16 October 2026
NCT03588299 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.